The Report is produced in Chinese only.

  02-09-2019 (星期一) 中國嬰幼兒配方奶粉市場增長放緩,高端及超高端料成為增長動力
  19-08-2019 (星期一) 擴大醫療器械註冊人制度試點,國內醫療器械龍頭將受惠
  05-08-2019 (星期一) 上海自貿區擴容加快落地預期升溫
  22-07-2019 (星期一) 互聯網平臺經濟迎利好,支持社會資本進入醫療健康等服務領域
  08-07-2019 (星期一) 中央政策支持內需 留意啤酒龍頭企業
[第3頁 / 共55頁]



這是中國從2009年開始推廣新能源汽車至今,首次出現年度銷量下滑。全年銷量也沒有達到下調之後150萬輛的原定目標,可以說是踩了刹車。主要原因是去年以來,受宏觀經濟壓力、國五排放車型降價銷售擠出效應、新能源汽車財政補貼大幅退坡等多重因素叠加影響所致。2019新能源補貼新政“過渡期”結束後,新能源車市從7月開始出現負增長。頭部企業如比亞迪,北汽新能源也未能幸免,其2019年累計新能源汽車銷量同比分別下滑7.39%, 4.69%,至22.95萬輛和15.06萬輛。



撰稿: 章晶研究分析員
+86 21 51699400-103

This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email :

Enquiry & Support
The Complaint Procedures
Louis Talk
Investor Notes
Free Subscribe
Contact Us